Nektar Therapeutics NKTR Common stock, shares authorized (in shares)
Common stock, shares authorized (in shares) at other companies
Other financials
Where this comes from
Reported directly by Nektar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.
The official record: Nektar Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nektar Therapeutics's common stock, shares authorized (in shares).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nektar Therapeutics's common stock, shares authorized (in shares)?
- Nektar Therapeutics (NKTR) reported common stock, shares authorized (in shares) of $390M in Q1 2026.
- How has Nektar Therapeutics's common stock, shares authorized (in shares) changed year-over-year?
- Nektar Therapeutics's common stock, shares authorized (in shares) increased by 30.0% year-over-year, from $300M to $390M.
- What is the long-term trend for Nektar Therapeutics's common stock, shares authorized (in shares)?
- Over 5 years (2020 to 2025), Nektar Therapeutics's common stock, shares authorized (in shares) has grown at a 5.4% compound annual growth rate (CAGR), from $300M to $390M.